radiopharmaceutical therapies

Oncology

The maximum dose of radiation prescribed by the FDA may be too conservative for novel therapies. But there's no easy solution to finding a new limit.

Oncology

The pharma industry is always on the lookout for new therapeutic angles that might prove to be a competitive advantage.

News

Vistagen has chalked up another trial failure for fasedienol, its drug candidate for social anxiety disorder.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.